| 摘要: |
| 大约70%的乳腺癌表达雄激素受体(androgen receptor, AR),研究数据表明雄激素受体可能在乳腺癌的发生机制中起重要作用,在某些难治性乳腺癌亚型中可以作为一种治疗靶点,比如三阴性乳腺癌(Triple-Negative Breast Cancer, TNBC)。临床上AR作为预后标志物及其在肿瘤中的功能作用尚不完全清楚。目前,乳腺癌中AR的研究已成为一个新的热点,本文就AR在乳腺癌中的研究现状作一综述。 |
| 关键词: 雄激素受体 乳腺癌 三阴性乳腺癌 |
| DOI：10.16118/j.1008-0392.2017.02.025 |
| 通信作者: |
| 投稿时间：2015-12-07 |
| 录用日期： |
| 基金项目:国家自然科学基金(81272240) |
|
| Progression on androgen receptor in breast cancer |
| 钟镇铧 |
| (Dept. of Breast and Thyroid Surgery, Tenth People's Hospital, Tongji University, Shanghai 200072, China) |
| Abstract: |
| About 70% of human breast cancers express androgen receptor(AR). Studies suggest that AR may play a role in pathogenesis of breast cancer and serve as a therapeutic target in certain types of breast cancer, such as triple-negative breast cancer(TNBC). Although this is an active research area, the clinical significance of AR as a prognostic marker and its role in tumorigenesis is unclear yet. At present, the research of AR in breast cancer becomes a new hotspot. This article reviews the research progress of the relationship between AR and breast cancer. |
| Key words: androgen receptor breast cancer triple-negative breast cancer |
